Ionis Pharmaceuticals (NASDAQ:IONS) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Analysts have recently evaluated Ionis Pharmaceuticals and provided 12-month price targets. The average target is $63.83, accompanied by a high estimate of $82.00 and a low estimate of $53.00. Marking an increase of 8.04%, the current average surpasses the previou…